Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Acta Neuropathol ; 128(6): 853-62, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25315281

RESUMEN

Although telomeres are maintained in most cancers by telomerase activation, a subset of tumors utilize alternative lengthening of telomeres (ALT) to sustain self-renewal capacity. In order to study the prevalence and significance of ALT in childhood brain tumors we screened 517 pediatric brain tumors using the novel C-circle assay. We examined the association of ALT with alterations in genes found to segregate with specific histological phenotypes and with clinical outcome. ALT was detected almost exclusively in malignant tumors (p = 0.001). ALT was highly enriched in primitive neuroectodermal tumors (12 %), choroid plexus carcinomas (23 %) and high-grade gliomas (22 %). Furthermore, in contrast to adult gliomas, pediatric low grade gliomas which progressed to high-grade tumors did not exhibit the ALT phenotype. Somatic but not germline TP53 mutations were highly associated with ALT (p = 1.01 × 10(-8)). Of the other alterations examined, only ATRX point mutations and reduced expression were associated with the ALT phenotype (p = 0.0005). Interestingly, ALT attenuated the poor outcome conferred by TP53 mutations in specific pediatric brain tumors. Due to very poor prognosis, one year overall survival was quantified in malignant gliomas, while in children with choroid plexus carcinoma, five year overall survival was investigated. For children with TP53 mutant malignant gliomas, one year overall survival was 63 ± 12 and 23 ± 10 % for ALT positive and negative tumors, respectively (p = 0.03), while for children with TP53 mutant choroid plexus carcinomas, 5 years overall survival was 67 ± 19 and 27 ± 13 % for ALT positive and negative tumors, respectively (p = 0.07). These observations suggest that the presence of ALT is limited to a specific group of childhood brain cancers which harbor somatic TP53 mutations and may influence the outcome of these patients. Analysis of ALT may contribute to risk stratification and targeted therapies to improve outcome for these children.


Asunto(s)
Neoplasias Encefálicas/genética , Carcinoma/genética , Neoplasias del Plexo Coroideo/genética , Glioma/genética , Tumores Neuroectodérmicos Primitivos/genética , Telómero , Proteína p53 Supresora de Tumor/genética , Adolescente , Neoplasias Encefálicas/fisiopatología , Carcinoma/fisiopatología , Neoplasias del Plexo Coroideo/fisiopatología , Estudios de Cohortes , ADN Helicasas/genética , Glioma/fisiopatología , Humanos , Estimación de Kaplan-Meier , Mutación , Clasificación del Tumor , Tumores Neuroectodérmicos Primitivos/fisiopatología , Proteínas Nucleares/genética , Fenotipo , Pronóstico , Telómero/metabolismo , Proteína Nuclear Ligada al Cromosoma X
2.
Acta Neuropathol ; 128(6): 863-77, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25120190

RESUMEN

Pediatric ependymomas are highly recurrent tumors resistant to conventional chemotherapy. Telomerase, a ribonucleoprotein critical in permitting limitless replication, has been found to be critically important for the maintenance of tumor-initiating cells (TICs). These TICs are chemoresistant, repopulate the tumor from which they are identified, and are drivers of recurrence in numerous cancers. In this study, telomerase enzymatic activity was directly measured and inhibited to assess the therapeutic potential of targeting telomerase. Telomerase repeat amplification protocol (TRAP) (n = 36) and C-circle assay/telomere FISH/ATRX staining (n = 76) were performed on primary ependymomas to determine the prevalence and prognostic potential of telomerase activity or alternative lengthening of telomeres (ALT) as telomere maintenance mechanisms, respectively. Imetelstat, a phase 2 telomerase inhibitor, was used to elucidate the effect of telomerase inhibition on proliferation and tumorigenicity in established cell lines (BXD-1425EPN, R254), a primary TIC line (E520) and xenograft models of pediatric ependymoma. Over 60 % of pediatric ependymomas were found to rely on telomerase activity to maintain telomeres, while no ependymomas showed evidence of ALT. Children with telomerase-active tumors had reduced 5-year progression-free survival (29 ± 11 vs 64 ± 18 %; p = 0.03) and overall survival (58 ± 12 vs 83 ± 15 %; p = 0.05) rates compared to those with tumors lacking telomerase activity. Imetelstat inhibited proliferation and self-renewal by shortening telomeres and inducing senescence in vitro. In vivo, Imetelstat significantly reduced subcutaneous xenograft growth by 40 % (p = 0.03) and completely abolished the tumorigenicity of pediatric ependymoma TICs in an orthotopic xenograft model. Telomerase inhibition represents a promising therapeutic approach for telomerase-active pediatric ependymomas found to characterize high-risk ependymomas.


Asunto(s)
Neoplasias Encefálicas/tratamiento farmacológico , Inhibidores Enzimáticos/farmacología , Ependimoma/tratamiento farmacológico , Indoles/farmacología , Células Madre Neoplásicas/efectos de los fármacos , Niacinamida/análogos & derivados , Telomerasa/antagonistas & inhibidores , Animales , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/enzimología , Carcinogénesis/efectos de los fármacos , Carcinogénesis/metabolismo , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Proliferación Celular/fisiología , Preescolar , Estudios de Cohortes , Supervivencia sin Enfermedad , Ependimoma/diagnóstico , Ependimoma/enzimología , Femenino , Humanos , Ratones , Recurrencia Local de Neoplasia/diagnóstico , Recurrencia Local de Neoplasia/enzimología , Trasplante de Neoplasias , Células Madre Neoplásicas/enzimología , Niacinamida/farmacología , Oligonucleótidos , Telomerasa/metabolismo , Telómero/efectos de los fármacos , Telómero/metabolismo
3.
Lancet Oncol ; 14(6): 534-42, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23598174

RESUMEN

BACKGROUND: Identification of robust biomarkers of malignancy and methods to establish disease progression is a major goal in paediatric neuro-oncology. We investigated whether methylation of the TERT promoter can be a biomarker for malignancy and patient outcome in paediatric brain tumours. METHODS: For the discovery cohort, we used samples obtained from patients with paediatric brain tumours and individuals with normal brain tissues stored at the German Cancer Research Center (Heidelberg, Germany). We used methylation arrays for genome-wide assessment of DNA. For the validation cohort, we used samples obtained from several tissues for which full clinical and follow-up data were available from two hospitals in Toronto (ON, Canada). We did methylation analysis using quantitative Sequenom and pyrosequencing of an identified region of the TERT promoter. We assessed TERT expression by real-time PCR. To establish whether the biomarker could be used to assess and predict progression, we analysed methylation in paired samples of tumours that transformed from low to high grade and from localised to metastatic, and in choroid plexus tumours of different grades. Finally, we investigated overall survival in patients with posterior fossa ependymomas in which the identified region was hypermethylated or not. All individuals responsible for assays were masked to the outcome of the patients. FINDINGS: Analysis of 280 samples in the discovery cohort identified one CpG site (cg11625005) in which 78 (99%) of 79 samples from normal brain tissues and low-grade tumours were not hypermethylated, but 145 (72%) of 201 samples from malignant tumours were hypermethylated (>15% methylated; p<0.0001). Analysis of 68 samples in the validation cohort identified a subset of five CpG sites (henceforth, upstream of the transcription start site [UTSS]) that was hypermethylated in all malignant paediatric brain tumours that expressed TERT but not in normal tissues that did not express TERT (p<0.0001). UTSS had a positive predictive value of 1.00 (95% CI 0.95-1.00) and a negative predictive value of 0.95 (0.87-0.99). In two paired samples of paediatric gliomas, UTSS methylation increased during transformation from low to high grade; it also increased in two paired samples that progressed from localised to metastatic disease. Two of eight atypical papillomas that had high UTSS methylation progressed to carcinomas, while the other six assessed did not progress or require additional treatment. 5-year overall survival was 51% (95% CI 31-71) for 25 patients with hypermethylated UTSS posterior fossa ependymomas and 95% (86-100) for 20 with non-hypermethylated tumours (p=0.0008). 5-year progression-free survival was 86% (68-100) for the 25 patients with non-hypermethylated UTSS tumours and 30% (10-50) for those with hypermethylated tumours (p=0.0008). INTERPRETATION: Hypermethylation of the UTSS region in the TERT promoter is associated with TERT expression in cancers. In paediatric brain tumours, UTSS hypermethylation is associated with tumour progression and poor prognosis. This region is easy to amplify, and the assay to establish hypermethylation can be done on most tissues in most clinical laboratories. Therefore the UTSS region is a potentially accessible biomarker for various cancers. FUNDING: The Canadian Institute of Health Research and the Terry Fox Foundation.


Asunto(s)
Biomarcadores de Tumor/genética , Neoplasias Encefálicas/genética , Metilación de ADN , Regiones Promotoras Genéticas , Telomerasa/genética , Edad de Inicio , Neoplasias Encefálicas/enzimología , Neoplasias Encefálicas/mortalidad , Neoplasias Encefálicas/patología , Islas de CpG , Supervivencia sin Enfermedad , Regulación Enzimológica de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Predisposición Genética a la Enfermedad , Estudio de Asociación del Genoma Completo , Alemania , Humanos , Estimación de Kaplan-Meier , Análisis Multivariante , Clasificación del Tumor , Ontario , Fenotipo , Modelos de Riesgos Proporcionales , Reacción en Cadena en Tiempo Real de la Polimerasa , Reproducibilidad de los Resultados , Estudios Retrospectivos , Factores de Tiempo , Sitio de Iniciación de la Transcripción
4.
Pediatr Pulmonol ; 57(6): 1440-1446, 2022 06.
Artículo en Inglés | MEDLINE | ID: mdl-35362672

RESUMEN

This cross-sectional study aims to utilize the Global Asthma Network (GAN) questionnaires to estimate the prevalence of asthma, allergic rhinitis, and eczema among children in Qatar. The study population was comprised of children ages 6-7 and 13-14 years, along with their parents or guardians. The English and Arabic versions of the GAN questionnaires were used to collect data for this study. A total of 2646 participants were recruited (1210 in the 6-7 years age group and 1436 in the 13-14 years age group), in addition to a total of 3831 parents or guardians. The overall prevalence of diagnosed asthma, lifetime allergic rhinitis, and diagnosed eczema in our study sample were as follows: 34.6%, 30.9%, and 37.4%, respectively. The current study showed an increased prevalence rate of asthma and eczema comparing to previous local estimates. These rates were higher in some cases or comparable in other cases to those found elsewhere. It is recommended that future research focus on studying the various factors contributing to the cases of asthma, allergic rhinitis, and eczema in Qatar. The reporting of this study conforms with the STROBE statement.


Asunto(s)
Asma , Eccema , Rinitis Alérgica , Rinitis , Adolescente , Asma/diagnóstico , Asma/epidemiología , Niño , Estudios Transversales , Eccema/diagnóstico , Eccema/epidemiología , Humanos , Prevalencia , Qatar/epidemiología , Rinitis/epidemiología , Rinitis Alérgica/epidemiología , Encuestas y Cuestionarios
5.
Rev. bras. educ. espec ; 22(4): 619-632, out.-dez. 2016.
Artículo en Portugués | LILACS | ID: biblio-829785

RESUMEN

RESUMO: dois objetivos são identificados no presente artigo: (a) contrastar o processo de desenvolvimento da leitura em pessoas com desenvolvimento típico e Transtorno do Espectro do Autismo (TEA) e (b) relatar os resultados de um estudo de revisão de pesquisas, publicadas em periódicos científicos, no período 2009-2015, sobre práticas interventivas em leitura, utilizadas no atendimento de indivíduos com TEA. Os resultados das pesquisas revelam que esses indivíduos, tipicamente, evidenciam déficits no processo de aquisição de competências em leitura. Assinale-se que os prejuízos na integração de informações, para fins de compreensão textual é prevalente, sendo apontado como um dos fatores críticos a serem tratados. Os problemas de leitura identificados nessa população podem, no entanto, ser remediados por meio de adaptações de estratégias empregadas com educandos com desenvolvimento típico. O artigo discute, por fim, a escassez de estudos nacionais que abordam essa temática e a carência de políticas educacionais que prezem pela adoção de modelos interventivos respaldados em pesquisas científicas.


ABSTRACT: Two objectives were identified in this article: (a) to contrast the reading development process in people with typical development and Autism Spectrum Disorder (ASD) and (b) to report the results of a review study focused on interventional practices published in scientific journals between 2009 and 2015. The results showed that individuals with ASD typically show deficits in reading development. Failure to integrate written information for textual understanding is prevalent and considerate a critical factor to be addressed. Reading problems identified in this population may, however, be remedied by adapting strategies commonly used with typically developing peers. The article further discusses the limited number of published national studies that address this issue and the lack of educational policies that support the use scientifically based practices.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA